Man Who Is Wrong About Everything Continues Streak With Take On Most Promising Cancer Drug In Decades
DURHAM, NC—Jason Locasale, a former professor whose primary research area is cancer metabolism and whose primary public contribution is being wrong on the internet, continued his unbroken streak Tuesday with a lengthy post arguing the first targeted therapy to show an overall survival benefit in pancreatic cancer is “hype.”
“After 40+ years of work and well over $100B in taxpayer funding, what’s being presented as a revolution is a survival improvement of about 6-7 months,” Locasale wrote, a sentence that manages to be simultaneously dismissive of the researchers who developed the drug, the patients who are alive because of it, and the concept of six months of human life. He recommended that funding be redirected toward “early detection and prevention,” a field in which he also does not work but which has the advantage of being impossible to criticize because no one can be against prevention, in the same way that no one can be against world peace or eliminating poverty, positions that are also easy to hold when you are not responsible for achieving them.
At press time, a pancreatic cancer patient who had enrolled in the daraxonrasib trial and whose tumor had shrunk by 76% was unaware that a former professor in North Carolina felt the result was insufficiently revolutionary, and was instead using his additional months to watch his daughter finish eighth grade.